{
  "success": true,
  "pagesUsed": [
    4,
    5,
    6,
    12,
    13,
    14
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Safety Objective",
        "text": "To assess the safety and tolerability of selonsertib (SEL), GS-0976, and GS-9674, administered alone or in combination, in subjects with bridging fibrosis or compensated cirrhosis due to NASH",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate changes in liver fibrosis, as measured by the NASH Clinical Research Network (CRN) classification, without worsening of NASH (defined as any increase in hepatocellular ballooning or lobular inflammation)",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Safety Endpoint",
        "text": "The safety of SEL, GS-0976, and GS-9674, alone or in combination... assessed during the study through the reporting of AEs, clinical laboratory tests, vital sign assessments, pruritus questionnaires, and concomitant medication usage.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_2",
        "name": "Primary Efficacy Endpoint",
        "text": "Proportion of subjects at Week 48 who achieve a ≥ 1-stage improvement in fibrosis (according to the NASH CRN classification) without worsening of NASH (defined as a ≥ 1-point increase in hepatocellular ballooning or lobular inflammation).",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Safety Estimand",
        "populationSummary": "Adults (18-80 years) with bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH Summary measure: Frequency and severity of adverse events and laboratory abnormalities.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study drug due to AE or other reasons",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death during the study period",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "SEL, GS-0976, and GS-9674 (alone or in combination) vs Placebo",
        "analysisPopulation": "Adults (18-80 years) with bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH",
        "variableOfInterest": "Safety and tolerability assessed through AEs, laboratory tests, vital signs, pruritus questionnaires, and concomitant medications",
        "summaryMeasure": "Frequency and severity of adverse events and laboratory abnormalities"
      },
      {
        "id": "est_2",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adults (18-80 years) with bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH Summary measure: Difference in proportions (point estimates and 95% confidence intervals).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Hepatic decompensation",
            "text": "Development of Child-Pugh score ≥ 7 or liver transplantation",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug prior to Week 48 biopsy",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_5",
            "name": "Missing Week 48 biopsy",
            "text": "Failure to obtain Week 48 liver biopsy for assessment",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "SEL, GS-0976, and GS-9674 (alone or in combination) vs Placebo",
        "analysisPopulation": "Adults (18-80 years) with bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH",
        "variableOfInterest": "Proportion of subjects at Week 48 who achieve a ≥ 1-stage improvement in fibrosis (NASH CRN) without worsening of NASH",
        "summaryMeasure": "Difference in proportions (point estimates and 95% confidence intervals)"
      }
    ],
    "summary": {
      "primaryObjectives": 2,
      "secondaryObjectives": 0,
      "exploratoryObjectives": 0,
      "totalEndpoints": 2,
      "totalEstimands": 2
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Safety Objective",
        "text": "To assess the safety and tolerability of selonsertib (SEL), GS-0976, and GS-9674, administered alone or in combination, in subjects with bridging fibrosis or compensated cirrhosis due to NASH",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate changes in liver fibrosis, as measured by the NASH Clinical Research Network (CRN) classification, without worsening of NASH (defined as any increase in hepatocellular ballooning or lobular inflammation)",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Safety Endpoint",
        "text": "The safety of SEL, GS-0976, and GS-9674, alone or in combination... assessed during the study through the reporting of AEs, clinical laboratory tests, vital sign assessments, pruritus questionnaires, and concomitant medication usage.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_2",
        "name": "Primary Efficacy Endpoint",
        "text": "Proportion of subjects at Week 48 who achieve a ≥ 1-stage improvement in fibrosis (according to the NASH CRN classification) without worsening of NASH (defined as a ≥ 1-point increase in hepatocellular ballooning or lobular inflammation).",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Safety Estimand",
        "populationSummary": "Adults (18-80 years) with bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH Summary measure: Frequency and severity of adverse events and laboratory abnormalities.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study drug due to AE or other reasons",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death during the study period",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "SEL, GS-0976, and GS-9674 (alone or in combination) vs Placebo",
        "analysisPopulation": "Adults (18-80 years) with bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH",
        "variableOfInterest": "Safety and tolerability assessed through AEs, laboratory tests, vital signs, pruritus questionnaires, and concomitant medications",
        "summaryMeasure": "Frequency and severity of adverse events and laboratory abnormalities"
      },
      {
        "id": "est_2",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adults (18-80 years) with bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH Summary measure: Difference in proportions (point estimates and 95% confidence intervals).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Hepatic decompensation",
            "text": "Development of Child-Pugh score ≥ 7 or liver transplantation",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug prior to Week 48 biopsy",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_5",
            "name": "Missing Week 48 biopsy",
            "text": "Failure to obtain Week 48 liver biopsy for assessment",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "SEL, GS-0976, and GS-9674 (alone or in combination) vs Placebo",
        "analysisPopulation": "Adults (18-80 years) with bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH",
        "variableOfInterest": "Proportion of subjects at Week 48 who achieve a ≥ 1-stage improvement in fibrosis (NASH CRN) without worsening of NASH",
        "summaryMeasure": "Difference in proportions (point estimates and 95% confidence intervals)"
      }
    ]
  }
}